Finance
Eli Lilly stock gets bump after results for its mid-stage diabetes drug trial shows positive results (LLY)
- On Thursday, pharma giant Eli Lilly and Co. announced positive results in a mid-stage trial for its experimental new diabetes drug. The company’s stock rose 3% on the news.
- The drug significantly reduced blood sugar levels and promoted weight loss in patients with type 2 diabetes.
- The late-stage trial for this drug is expected to be completed in 2021.
- This drug has to potential to boost Lilly’s growing portfolio of drugs extending across the areas of oncology, cardiovascular, diabetes, critical care, neuroscience, men’s health and musculoskeletal fields.
Continue Reading
-
Entertainment7 days ago
Apple Watch Series 9 vs. SE: A smartwatch skeptic tested both for 13 days
-
Business5 days ago
Google lays off workers, Tesla cans its Supercharger team and UnitedHealthcare reveals security lapses
-
Entertainment6 days ago
The greatest films on Prime Video right now
-
Business7 days ago
Google dubs Epic’s demands from its antitrust win ‘unnecessary’ and ‘far beyond the scope’ of the verdict
-
Entertainment2 days ago
iPad Pro 2024 now has OLED: 5 reasons this is a big deal
-
Entertainment6 days ago
Loneliness in kids: Screen time may play a role
-
Business5 days ago
The Rabbit r1 shipped half-baked, but that’s kind of the point
-
Business6 days ago
ICONIQ Growth raises $5.75B seventh flagship fund